Key result
Despite optimal reperfusion therapy for ST-elevation myocardial infarction, 5 to 6% of patients have a subsequent cardiovascular event by 30 days, highlighting the need for new treatment strategies.
Highlights the ongoing clinical need for strategies to mitigate myocardial reperfusion injury in STEMI patients despite optimal primary reperfusion therapies.
Every year, 500,000 people in the United States have an ST-elevation myocardial infarction.1 Timely and effective reperfusion with the use of either primary percutaneous coronary intervention (PCI) or thrombolytic therapy remains the most effective treatment strategy for limiting the size of the myocardial infarct, preserving left ventricular ejection fraction, and improving the clinical outcomes in such patients. However, despite optimal reperfusion therapy, morbidity and mortality remain substantial, with about 5 to 6% of patients having a subsequent cardiovascular event by 30 days.2 One treatment strategy that might reduce the size of the infarct and improve the clinical outcomes in these . . .
No takes yet. Share an insight, caveat, or question.
Hausenloy et al. (2008) conducted an editorial in ST-elevation myocardial infarction. Despite optimal reperfusion therapy for ST-elevation myocardial infarction, 5 to 6% of patients have a subsequent cardiovascular event by 30 days, highlighting the need for new treatment strategies.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: